Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MESO
stocks logo

MESO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 29.50 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 29.50 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 17.190
sliders
Low
24.00
Averages
29.50
High
35.00
Current: 17.190
sliders
Low
24.00
Averages
29.50
High
35.00
Jefferies
Hold
to
Buy
upgrade
$3
2025-11-25
Reason
Jefferies
Price Target
$3
2025-11-25
upgrade
Hold
to
Buy
Reason
Jefferies upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3.
Jefferies
David Stanton
Hold
to
Buy
upgrade
$3
2025-11-25
Reason
Jefferies
David Stanton
Price Target
$3
2025-11-25
upgrade
Hold
to
Buy
Reason
As previously reported, Jefferies analyst David Stanton upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3. Ryoncil continues to be rolled out and the firm forecasts 78 patients will complete therapy in FY26, up from 63, while updating its estimates for fiscal Q2 results and FY26 forecasts.
Jefferies
David Stanton
Buy
to
Hold
downgrade
2025-07-18
Reason
Jefferies
David Stanton
Price Target
2025-07-18
downgrade
Buy
to
Hold
Reason
Jefferies analyst David Stanton downgraded Mesoblast to Hold from Buy with a price target of A$2.60, up from A$2.50, following the fiscal Q4 report. The firm estimates 68 paid infusions were given during the quarter of Ryoncil in the U.S. with six patents likely having completed treatment. Jefferies updated fiscal 2025 estimates and awaits the company's annual results in August.
Piper Sandler
Edward Tenthoff
Buy
Reiterates
$15 → $24
2025-02-07
Reason
Piper Sandler
Edward Tenthoff
Price Target
$15 → $24
2025-02-07
Reiterates
Buy
Reason
Jefferies
David Stanton
Strong Buy
to
Hold
Downgrades
n/a
2024-12-23
Reason
Jefferies
David Stanton
Price Target
n/a
2024-12-23
Downgrades
Strong Buy
to
Hold
Reason
Jefferies downgraded Mesoblast to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company's for the FDA'ss recent approval of Ryoncil in pediatric steroids-refractory acute graft-versus-host disease patients. While the market size is only 375 pediatric patients per year in the U.S., expansion of this indication is possible in adults if the upcoming adult trial is positive, the analyst tells investors in a research note. Jefferies continues to assume full U.S. reimbursement approval at the start of fiscal 2026. However, after Mesoblast's recent share price appreciation, the firm downgraded the shares on valuation.
Piper Sandler
Edward Tenthoff
Buy
Maintains
$11 → $15
2024-12-19
Reason
Piper Sandler
Edward Tenthoff
Price Target
$11 → $15
2024-12-19
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Mesoblast Ltd (MESO.O) is -62.13, compared to its 5-year average forward P/E of -13.89. For a more detailed relative valuation and DCF analysis to assess Mesoblast Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-13.89
Current PE
-62.13
Overvalued PE
1.99
Undervalued PE
-29.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.43
Current EV/EBITDA
220.16
Overvalued EV/EBITDA
81.25
Undervalued EV/EBITDA
-98.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
29.45
Current PS
21.96
Overvalued PS
46.15
Undervalued PS
12.75
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

MESO News & Events

Events Timeline

(ET)
2025-11-20
18:38:16
Mesoblast partners with BMT CTN for Ryoncil trial in acute GvHD
select
2025-11-17 (ET)
2025-11-17
05:40:51
James O'Brien Named CFO of Mesoblast
select
2025-10-06 (ET)
2025-10-06
19:28:03
Mesoblast Announces 66% Year-over-Year Increase in Q2 Ryoncil Revenue
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-04Globenewswire
Mesoblast Participates in Piper Sandler Healthcare Conference, CEO to Speak
  • Conference Participation: Mesoblast is participating in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, where CEO Silviu Itescu is scheduled for a fireside chat on December 4 at 12:00 PM ET, highlighting the company's leadership in inflammatory diseases.
  • Technology Showcase: The event will feature a live webcast, allowing viewers to access the discussion via a provided link, which enhances the company's visibility and transparency among investors, potentially increasing interest from prospective investors.
  • Product Introduction: Mesoblast's Ryoncil® is the first FDA-approved mesenchymal stem cell therapy for treating steroid-refractory acute graft versus host disease in children, showcasing the company's innovative capabilities in cell therapy.
  • Intellectual Property Protection: Mesoblast holds over 1,000 patents covering its stem cell technology, ensuring commercial protection extending to 2044 in major markets, which strengthens the company's competitive position and long-term growth potential.
[object Object]
Preview
1.0
12-04Yahoo Finance
Mesoblast to Attend Piper Sandler Conference

  • Company Participation: Mesoblast Limited is participating in the Piper Sandler 37th Annual Healthcare Conference in New York from December 2–4, 2025, with a scheduled fireside chat by CEO Silviu Itescu on December 4.

  • Innovative Therapies: Mesoblast is a leader in developing allogeneic cellular medicines for severe inflammatory diseases, with its FDA-approved therapy Ryoncil® for pediatric patients with steroid-refractory acute graft versus host disease.

  • Intellectual Property and Manufacturing: The company holds over 1,000 patents related to its mesenchymal stromal cell technology, ensuring commercial protection until at least 2044, and utilizes proprietary manufacturing processes for scalable, off-the-shelf cellular medicines.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding Mesoblast's future performance and product development, emphasizing the inherent risks and uncertainties associated with such projections.

[object Object]
Preview
2.0
11-27Benzinga
Major Stocks on the Rise Wednesday: Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness, and More

  • U.S. Stock Market Performance: U.S. stocks rose on Wednesday, with the Dow Jones gaining over 300 points, driven by strong earnings reports from several companies.

  • Urban Outfitters Earnings Report: Urban Outfitters Inc. reported third-quarter earnings of $1.28 per share and revenue of $1.53 billion, both exceeding analyst expectations, leading to a 10.1% increase in its stock price.

  • Notable Stock Gains: Other companies like Falcon’s Beyond Global Inc. and Ironwood Pharmaceuticals saw significant stock price increases of 26% and 18.7%, respectively, following positive news and earnings reports.

  • Market Reactions to Company Announcements: Stocks such as Robinhood Markets and Petco Health and Wellness surged after announcing new initiatives and better-than-expected earnings, reflecting positive investor sentiment.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mesoblast Ltd (MESO) stock price today?

The current price of MESO is 17.19 USD — it has increased 1.54 % in the last trading day.

arrow icon

What is Mesoblast Ltd (MESO)'s business?

Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

arrow icon

What is the price predicton of MESO Stock?

Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 29.50 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mesoblast Ltd (MESO)'s revenue for the last quarter?

Mesoblast Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Mesoblast Ltd (MESO)'s earnings per share (EPS) for the last quarter?

Mesoblast Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Mesoblast Ltd (MESO)'s fundamentals?

The market is revising Upward the revenue expectations for Mesoblast Limited (MESO) for FY2026, with the revenue forecasts being adjusted by 26.03% over the past three months. During the same period, the stock price has changed by 19.46%.
arrow icon

How many employees does Mesoblast Ltd (MESO). have?

Mesoblast Ltd (MESO) has 81 emplpoyees as of December 05 2025.

arrow icon

What is Mesoblast Ltd (MESO) market cap?

Today MESO has the market capitalization of 2.17B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free